Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;20(9):1217-1224.
doi: 10.1038/nn.4598. Epub 2017 Jul 17.

Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder

Elaine T Lim  1   2   3   4 , Mohammed Uddin  5 , Silvia De Rubeis  6   7 , Yingleong Chan  3   4 , Anne S Kamumbu  1   2   3 , Xiaochang Zhang  1   2   3 , Alissa M D'Gama  1   2   3 , Sonia N Kim  1   2   3 , Robert Sean Hill  1   2   3 , Arthur P Goldberg  6   7 , Christopher Poultney  6   7 , Nancy J Minshew  8 , Itaru Kushima  9 , Branko Aleksic  9 , Norio Ozaki  9 , Mara Parellada  10 , Celso Arango  10 , Maria J Penzol  11 , Angel Carracedo  12   13   14 , Alexander Kolevzon  6   7   15   16   17 , Christina M Hultman  18 , Lauren A Weiss  19 , Menachem Fromer  6   7   20 , Andreas G Chiocchetti  21 , Christine M Freitag  21 ; Autism Sequencing Consortium; George M Church  3   4 , Stephen W Scherer  22   23   24   25 , Joseph D Buxbaum  6   7   15   16 , Christopher A Walsh  1   2   3
Collaborators, Affiliations

Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder

Elaine T Lim et al. Nat Neurosci. 2017 Sep.

Erratum in

Abstract

We systematically analyzed postzygotic mutations (PZMs) in whole-exome sequences from the largest collection of trios (5,947) with autism spectrum disorder (ASD) available, including 282 unpublished trios, and performed resequencing using multiple independent technologies. We identified 7.5% of de novo mutations as PZMs, 83.3% of which were not described in previous studies. Damaging, nonsynonymous PZMs within critical exons of prenatally expressed genes were more common in ASD probands than controls (P < 1 × 10-6), and genes carrying these PZMs were enriched for expression in the amygdala (P = 5.4 × 10-3). Two genes (KLF16 and MSANTD2) were significantly enriched for PZMs genome-wide, and other PZMs involved genes (SCN2A, HNRNPU and SMARCA4) whose mutation is known to cause ASD or other neurodevelopmental disorders. PZMs constitute a significant proportion of de novo mutations and contribute importantly to ASD risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1. De novo mutations in ASD show an excess of low alternate allele frequencies, consistent with post-zygotic mosaicism
(a) There is an excess of variants with low AAFs among the de novo mutations, which are likely to be post-zygotic mutations. (b) Rates of mutations in the datasets for all de novos in Group A, as well as mosaics in Groups B and C. (c) Correlation of AAFs for PZMs across the AAF spectrum using multiple technologies (n=49 mutations for CloneSeq, n=46 mutations for Pyroseq, n=42 mutations for MiSeq), with higher correlations (Pearson's r2=0.85 for CloneSeq and MiSeq, r2=0.63 for CloneSeq and Pyroseq). (d) Percentages of identified de novo variants that were identified by previous analyses or novel from Groups A, B and C. The majority of high-confidence PZMs from Group C were not detected by previous calling algorithms.
Figure 2
Figure 2. Post-zygotic mutations in ASD show excess deleterious mutations in critical exons of early developmental brain expressed genes
(a) There is no statistically significant global excess of Group C PZMs in the probands (red) compared to their unaffected siblings (blue), hypergeometric P=0.32 for fraction of LoF variants in probands compared to siblings. (b) As expected, there are highly significant excesses in overall gDNMs (Group A) for genes expressed in prenatal and adult brains. For Groups B and C, representing potential and high-confidence PZMs, there is a strong excess of LoF and missense mutations in critical exons that are expressed in EPN (early prenatal) and LPN (late prenatal), 1-tailed Wilcoxon rank sum test P<1×10-5, but not ECH (early childhood) or ADU (adult) post-mortem brain samples in the probands, 1-tailed Wilcoxon rank sum test P>1×10-5.
Figure 3
Figure 3. Post-zygotic mutations implicate the prenatal amygdala in ASD
Spatial representation of the regions that are enriched for PZMs in Group C in the probands, and the 1-tailed Wilcoxon rank sum test P=5.4×10-3 for the top brain region (AMY – amygdala).
Figure 4
Figure 4. Recurrent non-synonymous post-zygotic mosaic mutations implicate novel genes with more mutations than expected false calls
(a) Sanger sequencing traces for the 3 SMARCA4 mutations. (b) SMARCA4 mutations reported in cancers, Coffin-Siris syndrome and ASD. (c) qPCR results for GRIN2B after overexpression and selection of wildtype and mutant (p.P143A and p.I184T) human SMARCA4 in N2A cells, with the values for each replicate experiment (N=3 each for WT, P143A and I184T) in red dots (unpaired t-test P=0.0031 for P143A compared to wildtype and P=0.015 for I184T compared to wildtype).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gaugler T, et al. Most genetic risk for autism resides with common variation. Nature genetics. 2014;46:881–885. doi: 10.1038/ng.3039. - DOI - PMC - PubMed
    1. Sanders SJ, et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. Neuron. 2015;87:1215–1233. doi: 10.1016/j.neuron.2015.09.016. - DOI - PMC - PubMed
    1. Pinto D, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. American journal of human genetics. 2014;94:677–694. doi: 10.1016/j.ajhg.2014.03.018. - DOI - PMC - PubMed
    1. De Rubeis S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–215. doi: 10.1038/nature13772. - DOI - PMC - PubMed
    1. Iossifov I, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515:216–221. doi: 10.1038/nature13908. - DOI - PMC - PubMed